Clinical Study On The Effect Of Ulcerative Colitis In Patients With Spleen - Kidney - Yang Deficiency

Purpose:To observe clinical effects of self-developed Yu Kui formula on maintaining remission of Yang deficiency of spleen and kidney type ulcerative colitis.Methods:41 cases of spleen and kidney Yang deficiency type ulcerative colitis patients were randomly divided into treatment group and control group. The treatment group including 20 cases was given the self-developed Yu Kui formula orally. The control group had 21 cases which was given the mesalazine SR granules(etiasa) orally. The two groups were followed for 1 year. Their maintain remission rate, adherence and adverse events were observed and evaluated.Results:1. At the end of the trail, the treatment group and control group respectively have 15 and 10 cases were still in maintaining remission. Kaplan Meier survival curve showed that the maintaining remission rate of the treatment group in ulcerative colitis was slightly better than that in control group. But there was no statistically significant difference.2. Neither of the two group patients had adverse events occurred.3. As to the compliance, 2 cases fall off in treatment group and 6 cases in control group. There was no statistically difference.Conclusion:1.Self-developed Yu Kui formula can effectively maintain remission of yang deficiency of spleen and kidney type ulcerative colitis. It’s curative effect is exact in anti- relapse.2.Self-developed Yu Kui formula can safely maintain remission of yang deficiency of spleen and kidney type ulcerative colitis.